Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT05755659

Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.

Conditions: Neoplasms

Sex: All

Phase: NA

Enrollment: 3000

Sponsor: Xijing Hospital

Location: China

Summary

To evaluate the safety of Fosaprepitant Dimeglumine Injection for the prevention of nausea and vomiting caused by tumor chemotherapy drugs, analyze the characteristics of the applicable population and clinical medication of Fosaprepitant Dimeglumine, evaluate the risk factors that may affect the efficacy of drug use, and compare the clinical benefits of different drug use modes.

Eligibility Criteria

Inclusion Criteria:Patients with nausea and vomiting caused by chemotherapyPatients who volunteered to participate in the studyExclusion Criteria:Hypersensitive to any component in this productPatients taking pimozide, terfenadine, astemizole and cisapride

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05755659). StuddyBuddy aggregates publicly available trial information.